ERK1/2 Antikörper

Produktnummer ABIN1724731

Dieses Maus Monoklonal-Antikörper erkennt spezifisch ERK1/2 in WB, ELISA, IHC und FACS. Er zeigt eine Reaktivität gegenüber Human und Maus und wurde in 1 Publikation erwähnt.

Kurzübersicht für ERK1/2 Antikörper (ABIN1724731)

Target: ERK1/2 (MAPK1/3) (Mitogen-Activated Protein Kinase 1/3 (MAPK1/3))

Reaktivität: Human, Maus

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser ERK1/2 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Flow Cytometry (FACS)

Klon: 3F8

Produktdetails anti-ERK1/2 Antikörper

Verwendungszweck: p44/42 MAPK (Erk1/2) Antibody

Aufreinigung: Ascitic fluid

Immunogen: Purified recombinant fragment of human MAPK expressed in E. Coli.

Isotyp: IgG2b

Anwendungsinformationen

Applikationshinweise:

ELISA: 1/10000

FCM: 1/200 - 1/400

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Ascitic fluid containing 0.03 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

Referenzen für anti-ERK1/2 Antikörper (ABIN1724731)

Lønne, Masoumi, Lennartsson, Larsson: "Protein kinase Cdelta supports survival of MDA-MB-231 breast cancer cells by suppressing the ERK1/2 pathway." in: The Journal of biological chemistry, Vol. 284, Issue 48, pp. 33456-65, (2009) (PubMed).

Details zu ERK1/2

Target: ERK1/2 (MAPK1/3) (Mitogen-Activated Protein Kinase 1/3 (MAPK1/3))

Andere Bezeichnung: p44/42 MAPK (Erk1/2)

Hintergrund: Mitogen-activated protein kinases (MAPKs) are a widely conserved family of serine/threonine protein kinases involved in many cellular programs such as cell proliferation, differentiation, motility, and death. The p44/42 MAPK (Erk1/2) signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors, and cytokines and is an important target in the diagnosis and treatment of cancer. Upon stimulation, a sequential three-part protein kinase cascade is initiated, consisting of a MAP kinase kinase kinase (MAPKKK or MAP3K), a MAP kinase kinase (MAPKK or MAP2K), and a MAP kinase (MAPK). Multiple p44/42 MAP3Ks have been identified, including members of the Raf family as well as Mos and Tpl2/Cot. MEK1 and MEK2 are the primary MAPKKs in this pathway. MEK1 and MEK2 activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187, respectively. Several downstream targets of p44/42 have been identified, including p90RSK and the transcription factor Elk-1. p44/42 are negatively regulated by a family of dual-specificity (Thr/Tyr) MAPK phosphatases, known as DUSPs or MKPs, along with MEK inhibitors such as U0126 and PD98059.

Molekulargewicht: 42 kDa

Gen-ID: 5594

UniProt: P28482